IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.945
AS - Asia 8.322
EU - Europa 5.646
SA - Sud America 2.341
AF - Africa 359
Continente sconosciuto - Info sul continente non disponibili 29
OC - Oceania 26
Totale 43.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.682
SG - Singapore 3.585
CN - Cina 2.161
BR - Brasile 2.011
HK - Hong Kong 1.241
SE - Svezia 1.199
RU - Federazione Russa 988
IT - Italia 752
DE - Germania 591
GB - Regno Unito 505
VN - Vietnam 493
UA - Ucraina 487
FI - Finlandia 443
CI - Costa d'Avorio 200
FR - Francia 191
IN - India 152
AR - Argentina 139
CA - Canada 139
ID - Indonesia 105
BD - Bangladesh 104
JP - Giappone 90
NL - Olanda 78
BE - Belgio 77
MX - Messico 71
AT - Austria 58
IQ - Iraq 58
EC - Ecuador 57
ZA - Sudafrica 57
TR - Turchia 56
ES - Italia 52
IR - Iran 51
PL - Polonia 51
IE - Irlanda 45
SA - Arabia Saudita 40
CO - Colombia 35
LT - Lituania 31
PK - Pakistan 29
VE - Venezuela 28
EU - Europa 24
PY - Paraguay 22
AU - Australia 20
EG - Egitto 20
UZ - Uzbekistan 19
CZ - Repubblica Ceca 17
JO - Giordania 17
MA - Marocco 17
CL - Cile 16
IL - Israele 16
PE - Perù 16
TN - Tunisia 15
KE - Kenya 14
AE - Emirati Arabi Uniti 13
JM - Giamaica 11
UY - Uruguay 11
BG - Bulgaria 10
KZ - Kazakistan 10
RO - Romania 10
TT - Trinidad e Tobago 10
DO - Repubblica Dominicana 9
GR - Grecia 9
OM - Oman 9
PT - Portogallo 9
AZ - Azerbaigian 8
NP - Nepal 8
AL - Albania 7
KR - Corea 7
MY - Malesia 7
BB - Barbados 6
CH - Svizzera 6
LB - Libano 6
NZ - Nuova Zelanda 6
SN - Senegal 6
BO - Bolivia 5
CR - Costa Rica 5
DZ - Algeria 5
EE - Estonia 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
DK - Danimarca 4
GE - Georgia 4
PA - Panama 4
BH - Bahrain 3
ET - Etiopia 3
HR - Croazia 3
HU - Ungheria 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
NG - Nigeria 3
QA - Qatar 3
A1 - Anonimo 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CY - Cipro 2
HN - Honduras 2
LY - Libia 2
MD - Moldavia 2
ME - Montenegro 2
Totale 43.632
Salva come PNG Salva come JPEG
Città #
Fairfield 3.851
Woodbridge 2.754
Ashburn 2.466
Houston 1.828
Chandler 1.816
Singapore 1.694
Seattle 1.529
Cambridge 1.299
Hong Kong 1.241
Wilmington 1.198
Jacksonville 1.162
Ann Arbor 1.141
Nyköping 895
Dallas 834
Beijing 614
Lawrence 448
Roxbury 432
Nanjing 381
Des Moines 299
Los Angeles 282
New York 277
Boardman 268
Princeton 238
Bari 228
Abidjan 200
San Diego 171
São Paulo 165
Brooklyn 151
Inglewood 148
Ho Chi Minh City 144
Buffalo 131
Santa Clara 126
Munich 120
London 114
Shenyang 93
Hebei 91
Norwalk 86
Dong Ket 85
Hanoi 85
Nanchang 85
Tokyo 84
Chicago 83
Moscow 79
Rio de Janeiro 78
Nuremberg 76
Dearborn 75
Jakarta 74
Helsinki 73
Jiaxing 72
Brussels 71
Guangzhou 67
Tianjin 67
Paris 65
North Bergen 52
Frankfurt am Main 51
Changsha 48
Toronto 48
Columbus 46
Belo Horizonte 44
Council Bluffs 41
Dublin 41
San Francisco 41
Montreal 40
The Dalles 40
Shanghai 39
Johannesburg 38
Warsaw 37
Amsterdam 36
Stockholm 35
Washington 35
Atlanta 34
Pune 34
Dhaka 32
Salt Lake City 32
Rome 30
Wuhan 29
Brasília 28
Marseille 28
Orem 28
Chennai 26
Curitiba 26
Denver 26
Phoenix 26
Milan 24
Vienna 24
Falls Church 23
Mottola 22
Poplar 22
Porto Alegre 22
Quito 22
Salvador 21
Zhengzhou 21
Boston 20
Campinas 20
Ribeirão Preto 20
San Mateo 20
Taranto 20
Baghdad 19
Jeddah 19
Jinan 19
Totale 31.583
Salva come PNG Salva come JPEG
Nome #
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study 313
The role of sexual dysfunction and attachment style in migraine related quality of life 212
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 210
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 202
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 195
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 193
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 189
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 188
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 185
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 185
Signs and symptoms of COVID-19 in patients with multiple sclerosis 184
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 180
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 180
Assessing response to interferon-β in a multicenter dataset of patients with MS 177
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 175
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 169
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 169
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 168
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 168
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 168
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 166
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 164
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 160
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 160
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 159
A rare case of multiple sclerosis and McArdle disease 158
Prognostic indicators in pediatric clinically isolated syndrome 158
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 157
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 157
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 154
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 153
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 149
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 149
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 148
Age-related changes of serum N-acetyl-aspartate in healthy controls. 147
Age-related disability in multiple sclerosis 146
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 145
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 145
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 143
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 143
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 142
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 141
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 140
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 140
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 139
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 138
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 136
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 136
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 136
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 136
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 135
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 134
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy 133
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 133
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 133
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis 133
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 131
Comparative efficacy of switching to natalizumab in active multiple sclerosis 131
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 131
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 130
A systematic review of the incidence and prevalence of cancer in multiple sclerosis 130
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 130
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 129
Multiple sclerosis registries in Europe – An updated mapping survey 129
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 128
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 128
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions 128
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 127
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 127
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 125
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 125
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 124
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 123
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 122
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 122
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 122
Treatment decisions in multiple sclerosis-insights from real-world observational studies 122
Psychosocial issue in children and adolescents with multiple sclerosis 121
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 120
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis 120
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study 119
Treating multiple sclerosis with natalizumab. 119
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 118
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 118
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 118
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies 117
Tissue distribution of the readthrough isoform of AQP4 reveals a dual role of AQP4ex limited to CNS 117
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. 116
Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation 116
A genome screen for multiple sclerosis in Italian families. 116
Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 115
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 115
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study 114
Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis 114
Development and validation of the ID-EC - The ITALIAN version of the identify chronic migraine 114
Defining secondary progressive multiple sclerosis 114
Long term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 113
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study 113
Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis 113
Natalizumab discontinuation and disease restart in pregnancy: A case series 113
Totale 14.393
Salva come PNG Salva come JPEG
Categoria #
all - tutte 196.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 196.940
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.106 0 0 0 0 0 369 513 403 426 655 418 322
2021/20223.282 235 422 48 80 144 289 174 172 237 210 532 739
2022/20234.809 779 506 297 427 616 590 66 558 714 30 126 100
2023/20241.647 153 312 108 110 144 354 60 59 30 63 29 225
2024/20257.632 321 145 641 302 238 631 586 638 373 423 1.102 2.232
2025/20268.246 2.257 776 1.514 1.799 1.654 246 0 0 0 0 0 0
Totale 45.205